Phio Pharmaceuticals to outline PH-762 next steps at Life Sciences Future 2026

Phio Pharmaceuticals will present a clinical development update on PH-762 at the Life Sciences Future 2026 Conference in King of Prussia, Pennsylvania, on Sept. 30. The company plans to discuss its completed Phase 1b study in cutaneous squamous cell carcinoma and upcoming clinical, regulatory and development milestones.

Why it matters: - Phio Pharmaceuticals is using the conference to signal the next phase for PH-762, its lead cancer program. - The update could shape investor expectations around clinical progress, regulatory timing and the program’s path in cutaneous squamous cell carcinoma. - The company is framing PH-762 as a potential non-surgical option for skin cancers.

What happened: - Phio Pharmaceuticals said it will present at the Life Sciences Future 2026 Conference, taking place Sept. 30 to Oct. 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania. - Robert Bitterman, Phio’s president and CEO, will give a clinical development update on PH-762. - The presentation is scheduled for Sept. 30 at 10:20 a.m. ET. - Phio said management will also take one-on-one meetings during the conference.

The details: - Phio plans to review its completed Phase 1b clinical study of PH-762 in cutaneous squamous cell carcinoma. - The company expects to outline next steps aimed at moving the program toward its next stage of clinical development. - Phio said the presentation will emphasize the favorable safety profile seen in Phase 1b. - The company also plans to discuss upcoming clinical, regulatory and development objectives tied to the PH-762 program. - Phio said PH-762 is an INTASYL siRNA gene silencing therapy designed to silence the PD-1 gene. - The Phase 1b trial, identified as NCT06014086, evaluated PH-762 in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. - Phio describes its INTASYL compounds as designed to help immune cells kill cancer cells more effectively. - The company’s website is more information. - Phio is also listed as a B2i Digital Featured Company, with an in-depth profile at the company profile.

Between the lines: - Phio is trying to turn a conference appearance into a broader proof point for PH-762 and the company’s INTASYL platform. - The timing suggests the company wants to keep attention on the program’s clinical momentum while it works through regulatory planning. - Management’s comments point to an effort to frame PH-762 as both a development asset and a partnering opportunity. - Phio said forward-looking milestones include FDA interactions and a comprehensive briefing package for the agency, though those steps remain subject to uncertainty.

What's next: - Phio said it expects to focus on the next stage of clinical development for PH-762 after the conference update. - The company said activities supporting that next phase are expected to be completed during the first quarter of 2027. - Investors and potential partners will be watching for more detail on FDA discussions, clinical trial design and development timelines. - Management will continue conference meetings during Life Sciences Future 2026.